South Korea · Delayed Price · Currency is KRW Orum Therapeutics Company Description
Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases in South Korea and the United States.
The company develops ORM-6151, which is in Phase I clinical trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes; ORM-1153, which is in pre-clinical trial for the treatment of acute myeloid leukemia and hematologic malignancies; and ORM-1023, which is in pre-clinical trial for the treatment of small cell lung cancer and neuroendocrine tumor.
It is also involved in the development of multiple programs for the treatment of solid tumors and immunology and inflammation; and E3 Ligase-DAC adaptor, an adaptor linker platform that conjugates protein degraders to antibodies and enables E3 ligase-based DACs.
The company was founded in 2016 and is headquartered in Daejeon, South Korea.
| Country | South Korea |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Sung-Joo Lee |
Contact Details
Address: 281-25 Munji-ro Daejeon, 34050 South Korea | |
| Phone | 82 4 2716 3030 |
| Website | orumrx.com |
Stock Details
| Ticker Symbol | 475830 |
| Exchange | KOSDAQ |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| ISIN Number | KR7475830006 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Sung-Joo Lee | Chief Executive Officer |